A. Asher

Efficacy and safety of the histamine H4 receptor antagonist ZPL‐3893787 in patients with atopic dermatitis

I. Osterloh, M. Yeadon, G. Layton, 2019, The Journal of allergy and clinical immunology.

In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.

R. Puri, R. Prayson, B. Joshi, 2001, Cancer research.

A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults

A. Nikkels, M. Yeadon, G. Layton, 2016 .

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis

E. Radue, C. Constantinescu, T. Sprenger, 2015, Neurology: Neuroimmunology & Neuroinflammation.